推荐产品
等级
pharmaceutical primary standard
API类
fluconazole
制造商/商品名称
USP
应用
pharmaceutical (small molecule)
包装形式
neat
SMILES字符串
FC1=CC(F)=C(C(CN2N=CN=C2)(O)CN3N=CN=C3)C=C1
InChI
1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2
InChI key
RFHAOTPXVQNOHP-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
相关类别
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
- Enhanced antifungal activity of fluconazole: A study optimized fluconazole-embedded transfersomal gel, demonstrating improved antifungal activity and compatibility. This research is crucial for enhancing fluconazole′s efficacy against resistant fungal strains, making it a pivotal tool in the fight against fungal infections (Cheng et al., 2024).
- Antifungal mechanisms against drug-resistant strains: Research on the antifungal activity of a trypsin inhibitor from chia seeds against fluconazole-resistant Candida species assessed its potential as a novel therapeutic approach. This study contributes valuable insights into natural compounds enhancing fluconazole′s effectiveness, crucial for developing alternative antifungal therapies (Nogueira et al., 2024).
- Advancements in fungal pathogenesis: The isolation and identification of Wickerhamiella tropicalis from blood culture using MALDI-MS highlight innovative diagnostic techniques that enhance the understanding of fungal pathogenesis. This research is essential for advancing microbial diagnostics and tailoring treatments to combat invasive fungal infections effectively (Takei et al., 2024).
生化/生理作用
氟康唑是一种抗真菌剂。是真菌细胞色素P-450甾醇C-14α-去甲基化的高选择性抑制剂。氟康唑是一种有效的CYP2C9抑制剂。氟康唑可干扰真菌麦角甾醇合成并下调金属硫蛋白基因。
氟康唑是一种抗真菌剂；是真菌细胞色素P-450甾醇C-14α-去甲基化的高选择性抑制剂。有效的CYP2C9抑制剂。干扰真菌麦角甾醇合成；下调金属硫蛋白基因。
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
警示用语：
Danger
危险分类
Acute Tox. 4 Oral - Aquatic Chronic 3 - Lact. - Repr. 1B
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Fluconazole in Sodium Chloride Injection
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 40(6), 1909-1909 (2018)
Fluconazole
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 43(6), 1901-1901 (2020)
Fluconazole in Dextrose Injection
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 40(6), 1907-1907 (2018)
Wei Zhao et al.
Clinical pharmacokinetics, 53(11), 1005-1018 (2014-08-27)
Selection of the first-dose-in-neonates is challenging. The objective of this proof-of-concept study was to evaluate a pharmacokinetic bridging approach to predict a neonatal dosing regimen. We selected fluconazole as a paradigm compound. We used data from studies in juvenile mice
Kim C M van der Elst et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 59(11), 1527-1533 (2014-08-26)
Fluconazole is recommended as first-line treatment in invasive candidiasis in children and infants. Although timely achievement of adequate exposure of fluconazole improves outcome, therapeutic drug monitoring is currently not recommended. We conducted a retrospective study of critically ill children treated
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门